The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $7.70

Today's change-0.73 -8.66%
Updated February 8 12:46 PM EST. Delayed by at least 15 minutes.
 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $7.70

Today's change-0.73 -8.66%
Updated February 8 12:46 PM EST. Delayed by at least 15 minutes.

Ironwood Pharmaceuticals Inc down (U.S.)$0.73

Ironwood Pharmaceuticals Inc is sharply lower today, dropping (U.S.)$0.73 or 8.66% to (U.S.)$7.70. Over the last five days, shares have lost 16.12% and sit 4.76% above their 52-week low. This security has underperformed the S&P 500 by 41.60% during the last year.

Key company metrics

  • Open(U.S.) $8.35
  • Previous close(U.S.) $8.43
  • High(U.S.) $8.71
  • Low(U.S.) $7.35
  • Bid / Ask(U.S.) $7.69 / (U.S.) $7.70
  • YTD % change-33.56%
  • Volume984,335
  • Average volume (10-day)1,327,529
  • Average volume (1-month)1,104,521
  • Average volume (3-month)1,225,870
  • 52-week range(U.S.) $7.35 to (U.S.) $17.00
  • Beta1.52
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.17
Updated February 8 12:46 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-123.79%

Although this company's net profit margin is negative, it is above the industry average and implies that Ironwood Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX1.48%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue40282938
Total other revenue--------
Total revenue40282938
Gross profit40202925
Total cost of revenue08013
Total operating expense66705771
Selling / general / administrative30333031
Research & development26292727
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)9------
Other operating expenses, total--------
Operating income-26-42-28-33
Interest income (expense), net non-operating-10-6-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax-47-48-33-38
Income after tax-47-48-33-38
Income tax, total------0
Net income-47-48-33-38
Total adjustments to net income--------
Net income before extra. items-47-48-33-38
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-47-48-33-38
Inc. avail. to common incl. extra. items-47-48-33-38
Diluted net income-47-48-33-38
Dilution adjustment0--0--
Diluted weighted average shares142142141140
Diluted EPS excluding extraordinary itemsvalue per share-0.33-0.34-0.24-0.27
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.27-0.34-0.24-0.27